Clinical Trial Update: Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677 [Phase 1]

View source ↗

Summary

A Phase 1 single-dose escalation study to assess the safety and tolerability of GSK610677 in chronic obstructive pulmonary disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK610677

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED